AI assistant
Big Yellow Group PLC — Capital/Financing Update 2020
Apr 1, 2020
4821_rns_2020-04-01_a444cab8-2eb1-47d2-9446-94ecf0b1fb8e.html
Capital/Financing Update
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 3207I
Big Yellow Group PLC
01 April 2020
1 April 2020
Big Yellow Group PLC
("Big Yellow", "the Group" or "the Company")
New Aviva debt facility
As part of our ongoing management of our capital structure, Big Yellow decided in January to increase its borrowing with its long-standing lender Aviva.
We are therefore pleased to announce that we have completed a 7 year debt facility with Aviva of £35 million at an all-in cost of 1.96%, secured over the existing Aviva security pool of 15 stores. The all-in cost reduces to 1.91% following the installation of 50 kWh capacity solar panels at three of the stores.
The total debt facilities from Aviva are now £117.5 million of which £82.5 million will continue to amortise down to £60 million over the remaining seven years of the loan.
This new facility provides the Group with headroom of cash and undrawn bank facilities of £73 million.
The average cost of debt on drawn facilities is now 2.6% and the marginal cost of RCF bank debt remains at 1.35%
The Board has over the last few years worked to ensure a spread of debt maturity dates and to procure debt from a range of providers. The Group's earliest maturity is on its £70 million M&G loan in June 2023 and the Group's debt has an average maturity of 4.9 years.
| Enquiries: | |
| Nicholas Vetch, Executive Chairman | 01276 477811 |
| James Gibson, Chief Executive Officer | 01276 477811 |
| John Trotman, Chief Financial Officer | 01276 477811 |
| Teneo | 0203 603 5221 |
| Ben Foster | |
| Matt Denham |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCSDMESFESSEDD